Qidu Pharma, once again among the Top 100 Enterprises in Chinese pharmaceutical industries

On December 17-19, the 39th Annual Meeting of National Information of Pharmaceutical Industry & the 2021 Annual Conference of Top 100 Chinese Pharmacrutical Industries was convened at a grand presentation in Shanghai. Zidu pharmaceutical industry for nine consecutive years rongden Baiqiang board of Chinese pharmaceutical industry and scored the most investment value enterprise of Chinese pharmaceutical industry. General manager Jianyong Zhang attended the meeting and rose to the fore prize.

Sponsored by the China Center for pharmaceutical industry information, as one of the most influential industry congresses in China, the annual meeting adheres to the mission of empowering the Chinese pharmaceutical industry to upgrade innovation, with the theme of "" innovation · responsibility "", through focusing on several dimensions including the policy environment, innovation ecology, international trends, capital movements, and so on, by focusing on industry strategy, high-quality resources in chain industries, pooling policy landmarks, and recognizing industry punctuated enterprises, Insight into the development trend, pulse the market change, search for new industries in cooperation, and promote continuous industrial upgrading

Qilu pharmaceutical industry is again granted the top 100 board of the Chinese pharmaceutical industry and has been ranked the most investment value enterprise in the Chinese pharmaceutical industry, is the recognition by professional bodies of the comprehensive strength and innovation ability of the enterprise, and is the manifestation of the steady development of the enterprise and the wide brand influence recognized by the industry. In recent years, on the one hand, Zidu pharmaceutical industry deepen the cooperation between student and student, relies on the scientific research platform of the national enterprise technology center, postdoctoral scientific research workstation and provincial key laboratories, focuses on the evaluation of the consistency of generic drugs and the research and development of special process products, focuses on the high technical barriers dosage forms and Chinese medicinal products, and continuously promotes the competitive advantage of characteristic products. On the other hand, we will broaden the industrial chain, comprehensively strengthen the efforts to build up plates for high-end biological agents and featured crude drugs, and improve the construction of plates for pharmaceutical preparations, crude drugs and pharmaceutical intermediates, medical Packaging Materials, medical supplies and instruments, biomedicine, traditional Chinese medicine and big health six business plates strategy layout. At the same time, we should actively introduce a model of performance management excellence and comprehensive quality management, advance the standardization of scientific standardization of management, improve the overall performance and capability of the organization, and continuously create value for customers and other interested parties.

Qidu pharma will continue to adhere to the innovation driven strategy, continuously improve the level of corporate management and operational quality, so as to meet clinical medication needs as a hexon task and to attain quality as a guarantee, continuously improve the accessibility, affordability of high-quality medicines, and meet diverse health needs, and contribute more to the construction of powerful and healthy countries for pharmaceutical innovation.